Trial Profile
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Jul 2022
Price :
$35
*
At a glance
- Drugs Andecaliximab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms GAMMA-1
- Sponsors Gilead Sciences
- 12 Feb 2021 Results published in the Journal of Clinical Oncology
- 05 Jun 2019 This trial has been discontinued in Poland, according to European Clinical Trials Database.
- 28 May 2019 This trial has been completed in Hungary, according to European Clinical Trials Database.